Pre-existing biotherapeutic-reactive antibodies: Survey results within the american association of pharmaceutical scientists

AAPS Journal

Volumn 15, Issue 3, 2013, Pages 852-855

  Xue, Li ^a   Fiscella, Michele ^b   Rajadhyaksha, Manoj ^c   Goyal, Jaya ^d   Holland, Claire ^b   Gorovits, Boris ^a   Morimoto, Alyssa ^e  

^a PFIZER INC   (United States)

^b GLAXOSMITHKLINE   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d BIOGEN   (United States)

^e GENENTECH INC   (United States)

Author keywords

immunogenicity risk; pre existing antibodies; standardization

Indexed keywords

ANTI-DRUG ANTIBODY; ANTIBODY; BIOTHERAPEUTIC REACTIVE ANTIBODY; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL STUDY; DRUG EFFICACY; DRUG SAFETY; IMMUNOGENICITY; INCIDENCE; MEDICAL SOCIETY; PHARMACODYNAMICS; PHARMACOKINETICS; PREVALENCE; RISK BENEFIT ANALYSIS; RISK FACTOR;

ANTIBODIES; BIOLOGICAL FACTORS; BIOLOGICAL THERAPY; DATA COLLECTION; DRUG INDUSTRY; HUMANS; RISK FACTORS; SOCIETIES, SCIENTIFIC; UNITED STATES;

EID: 84879799027     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9492-4     Document Type: Article

References (2)

1. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med. 2008;358:1109-17.
2. Weeraratne D, Chen A, Pennucci JJ, et al. Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol. 2011;11:17. doi: 10.1186/1472-6904-11-17.